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This study explored the novel strategy of hypoxic preconditioning of Bone Marrow Mesenchymal 
Stem Cells (BM-MSCs) before intra vitreal transplantation to improve neuroprotective effects of 
Retinal Ganglion Cells (RGCs) in Acute Glaucoma Models. The methods of this research were iso-
lated mesenchymal stem cells from the bone marrow of adult wild-type Sprague-Dawley (SD) rats. 
BM-MSCs were cultured under normoxic or hypoxic (1% oxygen for 24 hours) conditions. Nor-
moxic or hypoxic BM-MSCs were transplanted intravitreally 1 week after ocular hypertension in-
duction by acutely increasing IOP to 100 - 120 mmHg for 60 minutes. Rats were killed 4 weeks af-
ter transplanted. Apoptosis was examined by tunnel assay and expression Brn3b (Brn3b = RGCs 
marker) by immunohistochemical analysis of the retina. Results showed that transplantation of 
hypoxic preconditioning BM-MSCs in acute glaucoma models resulted in a significant apoptosis 
decreasing (p < 0.05) and an significant increasing in RGCs (p < 0.05), as well as enhanced mor-
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phologic and functional benefits of stem cell therapy versus normoxic BM-MSCs transplantation. 
Conclusions: Hypoxic preconditioning enhances the capacity of BM-MSCs transplantation to im-
prove neuroprotective effects of RGCs in Acute Glaucoma Models.  
 
Keywords 





Glaucoma represents a group of diseases defined by a characteristic optic neuropathy that is consistent with ex-
cavation and undermining of the neural and connective tissue elements of the optic disc and by the eventual de-
velopment of distinctive patterns of visual dysfunction [1]. Glaucoma, a leading cause of irreversible visual loss, 
is characterized by loss of retinal ganglion cells (RGCs) and their axons over a period of many years. Glauco-
matous optic neuropathy is characterized by changes in the optic disc and visual field defects [2] [3]. The pa-
thophysiology of glaucoma is believed to be multifactorial [4] [5]. Elevated intraocular pressure (IOP) is one of 
the primary risk factors [1]. Until recently it was believed that elevated IOP plays a major role in RGCs apopto-
sis and it is also true that reduction of elevated IOP often helps in slowing down the progression of degenerative 
changes in glaucoma [4] [5]. 
The potential use of stem or progenitor cell transplantation to treat neurodegenerative diseases is a subject of 
intensive research [6]. Among stem cells that are candidates for transplantation in glaucoma patients, bone mar-
row mesenchymal stem cells (BMSCs) are preferred because they are available from autologous donation 
therefore eliminates ethical disputes and other concerns related to graft rejection [7]. Several in vitro and in vivo 
studies described conditions affecting on BM-MSCs to transdifferentiate into neural cells, either neurons or glial 
[8] [9]. BM-MSCs have a high predisposition to differentiate into preretinal-like cells with minimal time in cul-
ture. Brn3b and Ath5 gene expression increased markedly [10]. 
However, so far only a very small proportion of grafted cells have been shown to integrate into the host retina. 
Only ~1% of intraocularly transplanted cells commonly migrate into the retina, whereas most remain as a bolus 
outside of the neural tissue [11]. Replacement of retinal ganglion cells (RGCs) presents an even greater chal-
lenge [11]. Neuroprotective strategies, in which transplanted cells protect endogenous neural tissue, have also 
shown promising results in animal models of retinal disease. The neuroprotective mechanism of action appears 
to include trophic factor secretion and/or modulation of inflammatory processes [11]. In addition, cell transplan-
tation may activate endogenous repair mechanisms by modulating inhibitory signals to promote axonal regrowth 
and neuritic sprouting [12] [13]. 
Several strategies have been proposed to augment the longevity of engrafted cells in the hostile ischemic en-
vironment. These include the following: 1) treatment of the host tissue environment to make it more receptive 
for the donor cells; 2) in vitro manipulation (i.e., preconditioned donor cells); and 3) genetic modulation of the 
donor cells to make them more robust and resistant to apoptosis [14]. 
Hypoxic preconditioning BMSCs have been extensively investigated in various cell types, organs, animal 
models and humans [15]-[17]. Ischemic/hypoxic preconditioning activates endogenous defense mechanisms that 
show marked protective effects against multiple insults found in ischemic stroke and other acute attacks [15] 
[18]. Hypoxic preconditioning of transplanted BMSCs is an effective means of promoting their regenerative ca-
pability and therapeutic potential for the treatment of ischemic stroke [19]. 
Hypoxic preconditioning BMSCs increased expression of pro-survival and proangiogenic factors including 
hypoxia-inducible factor 1, angiopoietin-1, vascular endothelial growth factor and its receptor, Flk-1, erythro-
poietin, Bcl-2, and Bcl-xL. Cell death of hypoxic stem cells and caspase-3 activation in these cells were signifi-
cantly lower compared with those in normoxic stem cells both in vitro and in vivo [17]. The hypoxia exposure 
up-regulated HIF-1α and trophic/growth factors in BMSCs, including brain-derived neurotrophic factor (BDNF), 
glial cell-derived neurotrophic factor (GDNF), vascular endothelial growth factor (VEGF) and its receptor 
FIK-1, erythropoietin (EPO) and its receptor EPOR, stromal derived factor-1 (SDF-1) and its CXC chemokine 
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receptor 4 (CXCR4) [19]. BMSCs have an inhibitory action on inflammatory responses, which exacerbate 
ischemic damage; and they express a variety of neurotrophic and growth factors that may show autocrine and 
paracrine effects after transplantation [7] [20]. 
Hypoxic preconditioning BMSCs with 1% O2 was based on the state of each different organ levels of O2. 
Normal O2 levels inside the body vary by organ but are almost always substantially lower than the 20.8%. Cen-
tral nervous system (CNS) tissue PO2 values are conserved among mammalian species but vary by brain region. 
These range from as low as 0.55% (4.1 mmHg) in the midbrain to 8.0% (60 mmHg) in the pia. In rodents, the 
PO2 of cortical gray matter in rodents is 2.53% - 5.33% (19 - 40 mmHg) [21]. Normal PO2 at the mouse retinal 
surface was 21.7 ± 0.8 mmHg and the PO2 at the peak in the choroid was 42.0 ± 1.2 mmHg. The minimum PO2 
in the outer mouse retina was 4.2 ± 0.5 mmHg, and in the inner mouse retina it was 5.0 ± 0.5 mmHg [22]. 
The culture in hypoxic preconditioning BMSCs (1% - 3% O2) may also be beneficial for the BMSCs, as this 
oxygen tension is more similar to the physiologic niche for MSC in the bone marrow (2% - 7% O2) [23]. Altera-
tion of the duration of hypoxic conditions (oxygen concentrations < 2%) has been shown to have a contrasting 
role in stem cells (SCs). In a short period of time (under 48 h), hypoxia induced the proliferation, migration, and 
differentiation of various SCs, including BMSCs. Additionally, over a longer period of time (>72 h), hypoxia 
can reduce SC proliferation and/or lead to programmed cell death [24]-[26]. 
In this study, we hypothesize that the hypoxic preconditioning approach in BMSCs transplantation therapy 
can lead to decrease apoptosis and increase RGCs in animal model of Acute Glaucoma. 
2. Material and Methods 
2.1. Animal Experiment 
This experiment used adult (8 - 12 week old) male, weight 300 - 400 gram type Sprague-Dawley (SD) rats 
which was bred at Faculty of Veterinary Medicine, Airlangga University, Surabaya, Indonesia. All animals were 
housed in light- and temperature-controlled conditions and immunocompetent. All animal experiments operation 
prosedure were conducted with institutional of ethics approval in accordance with Animal Care and Use Com-
mittee (ACUC) the Faculty of Veterinary Medicine, Airlangga University, Surabaya, Indonesia. There were 
three groups of 24 SD rats. 
2.2. Isolation and Culture of Bone Marrow Mesenchymal Stem Cells (BM-MSCs) 
The procedure for isolation and culture of BM-MSCs were performed at Laboratory of Stem Cell, Institute of 
Tropical Disease, Airlangga University, Surabaya. Bone marrow-derived mesenchymal stem cells (BMSC) were 
cultured from the femoral and tibial bones of donor adult SD rats using a syringe and 20-gauge needle. The iso-
lation method was performed using Ficoll 0.077 density (Invitrogen). After centrifugation by 1600 rpm, 30 min 
were isolated mononucleates cells from Buffy coat space and washed using growth medium serum free and fol-
lowed centrifugation by 1600 rpm in 10 min. After that were cultured mononucleate cells in petridish 10 cm and 
growing in complete medium (α-MEM) (Invitrogen). Cultures were maintained at 37˚C in a humidified atmos-
phere containing 5% carbon dioxide. After 24 hours, nonadherent cells were discarded, and adherent cells were 
washed three times with phosphate-buffered saline solution (PBS). Fresh complete medium was added and re-
placed every 4 days. In second passage of mesenchymal stem cells phenotype were characterized by immuno-
cytochemistry and flow cytometry. Mesenchymal stem cells were labeled used PKH26 (Sigma, USA). 
2.3. Phenotypic Characterization BM-MSCs 
2.3.1. Immunocytochemistry 
Immunocytochemistry was used to characterize of phenotype rat Bone-Marrow derived Mesenchymal Stem Cell 
(rBMMSC) specific CD105 positive and CD45 negative. The cultured cells were plated onto coverslips and, af-
ter incubated at 37˚C for 1 - 2 hours, fixed with formaldehyde 10% for 15 minutes. The coverslips were then 
rinsed four times with PBS and let it dry for few minutes. The cells were blocked with for 1 hour in PBS con-
taining 1% bovine serum albumin (Sigma-Aldrich Corp) and 0.1% Triton X-100 (Sigma-Aldrich Corp) for 45 
min and then washed with PBS four times. FITC-labelled monoclonal antibody anti-rat CD105 and CD45 was 
applied to the cells and incubated for 60 minutes. Thereafter, the cells were rinsed with PBS twice and the cells 
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were imaged using an Olympus inverted fluorescent microscope. 
2.3.2. Flow Cytometry 
Flow cytometry was used to characterize of phenotype rat Bone-Marrow derived Mesenchymal Stem Cell 
(rBMMSC) specific CD105 positive, CD90 positive, CD34 negative and CD45 negative. Cells were incubated 
for 15 min with erythrocyte lysis buffer at 41˚C then were cells washed with PBS, and incubated with Dil-ac- 
LDL (acLDL) (10 mg/ml) for 1 hour at 37˚C. Cells were washed twice with plain medium, once with PBS, and 
fixed with 4% paraformaldehyde (PFA), and then cell were centrifuged at 1600 rpm for 10 min and resuspended 
in PBS containing 0.2% FCS and 2 mM EDTA. Cells were incubated using Rat MSCs Analysis Kit (BD Stem-
flowTM, BD Biosciences) with primary antibodies mouse anti-rat CD90, CD105, and negative antibodies con-
taining CD45, CD34 for 40 minutes. Labeled cells were analyzed by FACSCalibur flow cytometer (BD Bios-
ciences, Franklin Lakes, NJ, USA). 
2.4. Hypoxia Culture 
For hypoxic preconditioning (HP) treatment, cells were cultured until confluent. Fresh complete medium was 
added before hypoxia. Hypoxia treatment was controlled ProOx-C-chamber system (Biospherix, Redfield, NY) 
for 24 hours. The oxygen concentration in the chamber was maintained at 1% oksigen, with a residual gas mix-
ture composed of 5% carbon dioxide and balanced nitrogen. 
2.5. Animal Model of Acute Glaucoma 
All the experiment manipulations were carried under anesthesia with ketamine (50 mg/kg) and xylazine (10 
mg/kg) injected intramuscular. Local anesthetic 0.5% proparacaine hydrochloride was also applied topically to 
the cornea. The anterior chamber was cannuled with a 30-gauge needle connected to a syringe pump containing 
Balanced Salt Solution (BSS, Alcon Laboratories, Inc) under an operating microscope Inami. The IOP in expe-
rimental eyes was controlled with syringe pump, to maintain a pressure of 100 - 120 mmHg for 60 minutes [27] 
[28]. The final IOP was achieved after 2 - 3 minutes, and zero time for the ischemia was set. The flow of the 
pump was costantly monitored according to the pressure level. Retinal ischemia was achieved immediately with 
high IOPs, and it was confirmed by the blanching of the iris and retinal vascularitation. At the end of the 60 mi-
nutes of IOP elevation, the needle was removed, and reperfusion was confirmed by filling of the iris and retina 
vascularitation. Antibiotic drops Levofloxacin (LFX, Cendo Pharmaceuticals Inc. Indonesia) were applied topi-
cally after the prosedure. Experimental groups were divided into three groups of 8 rats each: 1) Glaucoma with 
transplant of normoxic BM-MSCs (N-BM-MSCs), 2) Glaucoma with transplant of hypoxic-precondisioning 
BM-MSCs (HP-BM-MSCs), 3) Glaucoma with no injection for precontrol (PC). 
2.6. Cell Preparation and Transplantation 
MSCs were labeled with PKH 26 to track and count the implanted cells. PKH 26 was added to culture medium 
for 2 hours before transplantation. Before transplantation, BM-MSCs in the HP group (HP-BM-MSCs) were 
treated for 24 hours with sublethal hypoxia (1% oxygen) and then reoxygenated in 20% oxygen for 2 hours. 
Seven days after IOP elevation rats 3 × 104 hypoxic preconditioning BM-MSCs (HP-BM-MSCs) in 3 µl sterile 
PBS were transplanted into the vitreous cavity of the left eye under anesthesia with ketamine (50 mg/kg) and 
xylazine (10 mg/kg) injected intramuscular. Local anesthetic was also applied topically to the cornea. Cells were 
injected through the superior nasal retina using a 30-gauge needle on a 5µl glass Hamilton syringe. Care was 
taken to ensure that the lens was not damaged and that the retinal blood supply was not affected. In a separate 
group received normoxic BM-MSCs (N-BM-MSCs). 
2.7. Tissue Preparation 
Rats were carried under anesthesia with ketamine (50 mg/kg) and xylazine (10 mg/kg) injected intramuscular 4 
weeks after IOP elevation. The eyes were enuclated and the globe was postfixed in 4% paraformaldehyde in 0.1 
mol/L phosphate-buffer saline for 4 hour. The cornea and lens were removed. Eyeballs were continuously sec-
tioned along the vertical meridian. Cryosections, including a full length of retina passing through the optic nerve 
head and the superior and inferior regions of the eye, were chosen for comparison among groups. 
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2.8. Terminal Deoxynucleotidyl Transferase Biotin-dUPT Nick End Labeling (TUNEL)  
in Retina Sections 
A TUNEL staining kit (DeadEnd Fluorometric TUNEL system, Promega, Madison, Wis) was used to visualize 
apoptotic cells in retina sections. After 10 minutes of fixing by 10% buffered formalin phosphate (Fisher Scien-
tific, Pittsburgh, Pa) and pretreatment with −20˚C ethanol/acetic acid (2:1) and 0.2% Triton X-100, the retina 
sections were incubated in an equilibration buffer as instructed by the kit. The TdT enzyme and nucleotide mix 
was then added at proportions specified by the kit for 75 minutes at room temperature. The slides were washed 
with 2X standard saline citrate washing buffer for 15 minutes and followed by three washings with PBS. 
2.9. Immunohistochemistry Analysis 
Immunohistochemistry on cryosections were blocked with goat serum for 1 hour at 37˚C and then incubated 
with primary antibodies for 24 hours at 4˚C, followed by secondary antibodies for 1 hour at 37˚C. Primary anti-
bodies included rat monoclonal antibody Brn3b. The positive cells were examined and mounted under inverted 
microscope. 
2.10. Statistic Analysis 
Experimental data were presented as mean ± SD. Statistical calculations were performed using SPSS13.0 (SPSS 
Inc., USA). The indexes among groups were compared by multiple comparisons. Statistical significance was de-
fined as p < 0.05. Data are expressed as the mean ± standard error of mean. 
3. Result 
3.1. Isolation and Culture of BM-MSCs 
The growth of the cells were observed for the first 24 hours, at which time the cells were mostly round or oval. 
After 24 hours, the majority of the cells were adherent to the plate and became spindle in shape. After 3 days, 
the cells grew to a confluence of 75% and ware arranged in swirling pattern [Figure 1(a)]. Before the cells were 
used for subsequent examination and transplantation, cell splitting procedure was performed 2 times. Before 
transplantation, BM-MSCs in the HP-BM-MSCs group were treated for 24 hours with sublethal hypoxia (1% 
oxygen) [Figure 1(c)] and BM-MSCs in the N-BM-MSCs group which were still cultured in 20% oxygen 
[Figure 1(b)]. 
3.2. The BM-MSCs Phenotypic Characterization 
3.2.1. Immunocytochemistry 
The immunocytochemistry showed that the target cells expressed strong mesenchymal stem cell marker CD105 
while weak expression of CD45 was noticed in N-BM-MSCs [Figure 2] and HP-BM-MSCs [Figure 3]. Ex-
pression of CD105 up to 80% on the surface membrane cells have important role, that mean were these cells al-
ready for transplantation, because it had showed an character of multipotent mesenchymal stem cells. 
3.2.2. Flow Cytometry 
The result of flowcytometry showed that majority of the target cells expressed strong CD90 and CD105, while 
CD45 and CD34 was expressed in small number of cells, which was noticed in N-BM-MSCs [Figure 4(a), 
Figure 4(b)] and HP-BM-MSCs [Figure 4(c), Figure 4(d)]. 
3.3. PKH26 Analysis 
Labeling using PKH 26 (Sigma-Aldrich, USA) is performed before BM-MSCs being inserted into the eyeball, 
On examination using a microscope fluorescent would looked BM-MSCs that have been labeled with PKH 26 
as in the yellowish orange [Figure 5]. 
On examination of the transplantation of BM-MSCs retinal tissue, it would looked fluorescence of the PKH 
26 along the layers of the retina [Figure 6]. This is to prove the homing of exogenous BM-MSCs entered via 
intravitreal on retinal tissue. 
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(a)                                    (b)                                    (c) 
Figure 1. (a) Culture of BM-MSCs on the first 24 hours the cells were mostly round or oval in shape; (b) Culture of BM- 
MSCs after 3 days the majority of the cells were adherent to the plate, showing spindle-shape with swirling-pattern colonies, 
and has reached confluence; (c) Culture of hypoxic precondisioning bone marrow mesenchymal stem cells (HP-BM-MSCs) 
showing spindle-shape with swirling-pattern colonies, and has reached conluence same with N-BM-MSCs (inverted micro-
scope, 200× magnification).                                                                                          
 
 
(a)                                         (b) 
Figure 2. Characterization of N-BM-MSCs by immunocytochemistry. Expression of (a) CD105, (b) CD45. Expression of 
CD105 up to 80% (inverted microscope, 200× magnification).                                                            
 
 
(a)                                         (b) 
Figure 3. Characterization of HP-BM-MSCs by immunocytochemistry. Expression of (a) CD105, (b) CD45 Expression of 
CD105 up to 80% (inverted microscope, 200× magnification).                                                           
3.4. TUNEL Analysis 
Examination of apoptosis in RGCs layer with Tunnel Assay painting to determine the number of cells under-
going apoptosis in retinal ganglion cell layer. The result of Tunnel Assay examination would show the lowest  
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(a)                                         (b) 
       
(c)                                          (d) 
Figure 4. (a) (b) Characterization of N-BM-MSCs by flowcytometry CD90 positive 
(80.98%), 105 positive (88.46%), CD45 negative and CD34 negative; (c) (d) Characteriza-
tion of HP-BM-MSCs by flowcytometry CD90 positive (88.37%), 105 positive (94.79%), 
CD45 negative and CD34 negative.                                                 
 
 
(a)                                         (b) 
Figure 5. PKH26 analysis on BM-MSCs. PKH26 fluoresces in the yellow-orange region of 
the spectrum. (a) N-BM-MSCs group in second passage; (b) HP-BM-MSCs group in second 
passage. Arrow showed PKH26 fluoresces in the yellow-orange region on BM-MSCs (in-
verted microscope, 200× magnification).                                             
 
number of undergoing apoptosis cells in the HP-BM-MSCs group compared with the other groups [Figure 7]. 
Apoptotic cells means on HP-BM-MSCs group 0.017 ± 0.041 would show the lowest number [Figure 8]. 




(a)                                         (b) 
Figure 6. PKH26 analysis on retinal ganglion cells layer four week after transplanted rom acute glaucoma animal models.  
(a) N-BM-MSCs group four week after transplanted N-BM-MSCs via intravitreal from acute glaucoma animal models. Ar-
row showed homing N-BM-MSCs in retinal ganglion cells layer with PKH26 fluoresces in the yellow-orange region; (b) 
HP-BM-MSCs group four week after transplanted PH-BM-MSCs via intravitreal from acute glaucoma animal models. Ar-
row showed homing PH-BM-MSCs in retinal ganglion cells layer (inverted microscope, 200× magnification).               
 
 
(a)                                  (b)                                  (c) 
Figure 7. TUNEL Analysis on RGCs layer. (a) Control group; (b) N-BM-MSCs group; (c) HP-BM-MSCs group. Arrow 
showed apoptotic cells in retinal ganglion cells layer (inverted microscope, 200× magnification).                             
 
 
Figure 8. Diagram of TUNEL Analysis on control group, N-BM-MSCs group and HP-BM-MSCs group. Apoptotic cells 
means on control group 0.533 ± 0.137; N-BM-MSCs group 0.623 ± 0.278; HP-BM-MSCs group 0.017 ± 0.041.                                          
 
Statistical data apoptotic cells mean the normality in each group was tested by using One Sample Kolmogo-
rov-Smirnov showing result of a normal distribution. Then continued Multiple Comparisons Test to determine 
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the differences between groups with p = 0.05. The results found a significant reduction in the number of cells 
undergoing apoptosis with p < 0.05 in the HP-BM-MSCs group against control group and N-BM-MSCs group. 
3.5. Immunohistochemistry 
Examination of Brn3b expression in retinal tissue with immunohistochemical staining is to determine the num-
ber of RGCs [Figure 9]. The result of Brn3b expression immunohistochemistry examination showed an increase 
in the number of RGCs in HP-BM-MSCs group (40.950) compared with other groups [Figure 10]. The lowest 
was in the control group. 
Statistical data Brn3b means (RGCs) means the normality of each group was tested by using One Sample 
Kolmogorov-Smirnov showing results of a normal distribution. Then continued with Multiple Comparisons Test 
to determine the differences between groups with p = 0.05. The results found a significant enhancement in the 
number of RGCs with p < 0.05 in the HP-BM-MSCs group against control and N-BM-MSCs group. 
4. Discussion 
MSC is multipotent stem cell, that has a plasticity properties, and also have many kinds of protein as markers or 
signal expressed on the surface membrane cell have important role in communication between cell. CD105 is 
relative stable markers of MSC, because many kinds of markers can be used for detection of MSCs like CD90, 
 
 
(a)                                  (b)                                  (c) 
Figure 9. Immunohistochemistry analysis of Brn3b expression four week after transplanted from acute glaucoma 
animal models. (a) Control group five weeks after intra ocular pressure reduction on acute glaucoma animal mod-
els. Arrow showed Brn3b expression on retinal ganglion cells layer; (b) N-BM-MSCs group four week after 
transplanted N-BM-MSCs. Arrow showed Brn3b expression on retinal ganglion cells layer; (c) HP-BM-MSCs 
group four week after transplanted PH-BM-MSCs. Arrow showed Brn3b expression on retinal ganglion cells 
layer (inverted microscope, 400× magnification).                                                            
 
 
Figure 10. Diagram of Brn3b expression on control group, N-BM-MSCs group and HP-BM-MSCs group. Brn3b 
expression means on control group 1.167 ± 0.592; N-BM-MSCs group 18.245 ± 4.910; HP-BM-MSCs group 
40.950 ± 9.431.                                                                                            
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CD73 and cells did not express CD34, CD11b, CD19, CD45 and HLA-DR [29]-[31]. In this research, we used 
HP-BM-MSCs with expression of CD90 positive (88.37%), 105 positive (94.79%) and N-BM-MSCs with ex-
pression of CD90 positive (80.98%), 105 positive (88.46%). 
BM-MSCs have the ability to differentiate into neuroectodermal cell types in vitro and also in vivo after 
transplantation into the human brain and spinal cord [9]. 
BM-MSCs were cultivated in a neuroinduction mix medium for 24 h showed that Brn3b and Ath5 gene ex-
pression increased markedly. These results suggest that BM-MSCs have a high predisposition to differentiate 
into preretinal-like cells with minimal time in culture [10]. 
BM-MSCs have an important role in tissue engineering and regenerative medicine due to their immunogenic-
ity, for the ability to perform immunomodulatory and anti-inflammatory functions. They have ability to secrete 
multiple bioactive molecules able of stimulating recovery of injured cells [32]. 
Intraocular transplantation of stem cells for retinal therapy can be achieved via two approaches, either subre-
tinally or intravitreally, with each technique possessing advantages and disadvantages for particular applications. 
Subretinal injections leave cells physically constrained adjacent to the outer retina and near to rich blood supply, 
whereas intravitreal injections are technically simpler and provide direct access to the inner retina [31]. In this 
research, we used intravitreally transplanted cells. 
Glaucoma is a common neurodegenerative disease of the inner retina. In the context of inner retinal disease, 
intravitreal injections are likely to be more applicable than subretinal injections. the ECM of the inner basal la-
mina is neither necessary nor sufficient to prevent migration of transplanted cells into the neural retina. In con-
trast, glial reactivity was associated with poor graft migration. Targeted disruption of glial reactivity dramatical-
ly improved the structural integration of intravitreally transplanted cells [31]. 
BMSCs subretinal transplantation could inhibit photoreceptor apoptosis and slow down retinal damage in 
light-damaged rat eyes. Transplanted BMSCs survived in the subretinal space and ONL but did not differentiate 
into neural cells or retinal cells. BMSCs have the capacity to produce some kinds of trophic factors in the light- 
damaged model eye and in vitro cultivation with light-damaged SHR, which might have trophic and protective 
effects on light-damaged retina [33]. 
In ischemic/hypoxic environment, BMSC transplantation has been low homing and survival rates of BMSCs 
and of the observation that the functional benefits after BMSC transplantation has been attributed to increased 
trophic support but not cell replacement cortex cerebri is extremely low (e.g. ~0.01% of total inj [34]. The hom-
ing of systemically administered BMSCs to the ischemic ected cells) [35]. Johnson, 2010 and others have re-
ported that only ~1% of intraocularly transplanted cells commonly migrate into the retina, whereas most remain 
as a bolus outside of the neural tissue. 
Strategies have been proposed to augment the longevity of engrafted cells in the hostile ischemic environment 
is in vitro manipulation (i.e., preconditioned donor cells) [14]. In this research, we used hypoxic preconditioning 
1% O2. 
HP treatment promotes survival of transplanted cells in the ischemic brain and heart [15] [17] [36]. Hypoxic 
preconditioning increased expression of several trophic/growth factors in MSCs [19]. 
In ischemic/hypoxic preconditioning and neuroprotection against ischemic injury, HIF-1α and HIF-1β play 
central roles [36] [37] [39]. Its translocation and activation in the nucleus result in production of several down-
stream genes such as vascular endothelial growth factor (VEGF), erythropoietin (EPO), glial cell line-derived 
neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) all are im-
portant for brain protection and tissue regeneration [36]-[38]. 
Transplantation of hypoxic versus normoxic BM-MSCs after myocardial infarction resulted in an increase in 
angiogenesis, as well as enhanced morphologic and functional benefits of stem cell therapy. Hypoxic precondi-
tioning increased expression of pro-survival and proangiogenic factors including hypoxia-inducible factor 1, an-
giopoietin-1, vascular endothelial growth factor and its receptor, Flk-1, erythropoietin, Bcl-2, and Bcl-xL. Cell 
death of hypoxic stem cells and caspase-3 activation in these cells were significantly lower compared with that 
in normoxic stem cells both in vitro and in vivo [17]. 
HP can decrease apoptosis of neurons through induction of hypoxia-inducible factor-1α (HIF-1α) [39] and 
protect myocytes from hypoxia and reperfusion injury [18]. 
Microglia, cells of the monocyte/macrophage lineage in the brain, have been implicated in the pathogenesis of 
a number of neurodegenerative [40]. As part of the innate immune defense mechanism, microglia can defend the 
central nervous system against damage, but increasing evidence suggest that excessive or sustained microglia 
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activation can significantly contribute to acute and chronic neuropathologies and apoptotic cell death. Dysregu-
lation of microglial cytokine production could thereby promote harmful actions of the defense mechanisms, re-
sult in direct neurotoxicity, as well as disturb neural cell functions [41]-[43]. 
5. Conclusions 
Hypoxic preconditioning of transplanted cells provides a new and effective strategy for cell-based therapy in the 
treatment of ischemic diseases. Hypoxic preconditioning enhances the capacity of BM-MSCs to improve neuro-
protective effects in Acute Glaucoma Models. 
The mechanism of the therapeutic benefits must be multifaceted, and at least involve enhanced expression and 
release of trophic/growth factors that provide autocrine and paracrine effects of protection and stimulation of 
regenerative responses. 
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